Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Total Non-Current Liabilities (2019 - 2023)

Historic Total Non-Current Liabilities for Marker Therapeutics (MRKR) over the last 6 years, with Q2 2023 value amounting to $2.9 million.

  • Marker Therapeutics' Total Non-Current Liabilities fell 7300.42% to $2.9 million in Q2 2023 from the same period last year, while for Jun 2023 it was $2.9 million, marking a year-over-year decrease of 7300.42%. This contributed to the annual value of $7.0 million for FY2022, which is 3741.67% down from last year.
  • Per Marker Therapeutics' latest filing, its Total Non-Current Liabilities stood at $2.9 million for Q2 2023, which was down 7300.42% from $6.8 million recorded in Q1 2023.
  • Marker Therapeutics' Total Non-Current Liabilities' 5-year high stood at $11.9 million during Q3 2020, with a 5-year trough of $226111.0 in Q1 2020.
  • Its 5-year average for Total Non-Current Liabilities is $7.0 million, with a median of $8.1 million in 2020.
  • In the last 5 years, Marker Therapeutics' Total Non-Current Liabilities skyrocketed by 508321.8% in 2021 and then plummeted by 7300.42% in 2023.
  • Quarter analysis of 5 years shows Marker Therapeutics' Total Non-Current Liabilities stood at $280247.0 in 2019, then surged by 4134.99% to $11.9 million in 2020, then fell by 5.23% to $11.2 million in 2021, then crashed by 37.42% to $7.0 million in 2022, then plummeted by 58.51% to $2.9 million in 2023.
  • Its Total Non-Current Liabilities stands at $2.9 million for Q2 2023, versus $6.8 million for Q1 2023 and $7.0 million for Q4 2022.